Cargando…

Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective

Detalles Bibliográficos
Autores principales:	Sönmez, Mehmet, Kestane, Merve, Akıdan, Osman, Erkut, Nergiz, Bektaş, Özlen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656115/ https://www.ncbi.nlm.nih.gov/pubmed/34792306 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0435

Ejemplares similares

Assessment of Long-Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine
por: Sönmez, Bircan, et al.
Publicado: (2021)

Effect of Clinical, Endoscopic, Radiological Findings, and Complications on Survival in Patients with Primary Gastrointestinal Lymphoma
por: Erkut, Murat, et al.
Publicado: (2022)

Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia
por: Mentese, Ahmet, et al.
Publicado: (2018)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia
por: Menteşe, Ahmet, et al.
Publicado: (2017)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

White blood cell count profile in patients with physical complaints without known causes
por: Akaishi, Tetsuya, et al.
Publicado: (2022)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Herling, Carmen D., et al.
Publicado: (2018)

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects
por: Tariq, Saba, et al.
Publicado: (2020)

Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia
por: Molica, Stefano
Publicado: (2020)

Improved count rate corrections for highest data quality with PILATUS detectors
por: Trueb, P., et al.
Publicado: (2012)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Treatment of childhood lymphocytic leukaemia with high white-cell counts.
por: Ekert, H., et al.
Publicado: (1978)

P641: REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA
por: Teschemaker, Anna, et al.
Publicado: (2023)

The human fungal pathogen Aspergillus fumigatus can produce the highest known number of meiotic crossovers
por: Auxier, Ben, et al.
Publicado: (2023)

Venetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic Leukemia
por: Borg, Michelle A., et al.
Publicado: (2017)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
por: Abdel-Samad, Nizar, et al.
Publicado: (2021)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
por: Avsec, Damjan, et al.
Publicado: (2021)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Phylogeographic studies of schizothoracine fishes on the central Qinghai-Tibet Plateau reveal the highest known glacial microrefugia
por: Liang, Yangyang, et al.
Publicado: (2017)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Diagnostic accuracy of complete blood cell count and neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios for neonatal infection
por: Kurt, Abdullah, et al.
Publicado: (2022)

Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary” during venetoclax treatment?
por: Dimou, Maria, et al.
Publicado: (2021)

Can Eosinophil Count, Platelet Count, and Mean Platelet Volume Be a Positive Predictive Factor in Penile Arteriogenic Erectile Dysfunction Etiopathogenesis?
por: Sönmez, Mehmet Giray, et al.
Publicado: (2016)

The second highest chromosome count among vertebrates is observed in cultured sturgeon and is associated with genome plasticity
por: Havelka, Miloš, et al.
Publicado: (2016)

Blood count parameters can predict the severity of coronary artery disease
por: Uysal, Hilal Bektas, et al.
Publicado: (2016)

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)

Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease
por: Sugiura, Hiroyuki, et al.
Publicado: (2022)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter’s syndrome
por: Tutaeva, Victoria Vladimirovna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8usfsdjo7c7taiqjgn60ntv6h1